Klekota J, Brauner E, Schreiber SL. Identifying biologically active compound classes using phenotypic screening data and sampling statistics. J Chem Inf Model. 2005;45(6):1824-36. doi:10.1021/ci050087d.

Hu L, Magesh S, Chen L, et al. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg Med Chem Lett. 2013;23(10):3039-43. doi:10.1016/j.bmcl.2013.03.013.

Martinez EJ, Owa T, Schreiber SL, Corey EJ. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. Proc Natl Acad Sci U S A. 1999;96(7):3496-501.

Bajorath J, Peltason L, Wawer M, Guha R, Lajiness MS, Van Drie JH. Navigating structure-activity landscapes. Drug Discov Today. 2009;14(13-14):698-705. doi:10.1016/j.drudis.2009.04.003.

Reczek CR, Birsoy K, Kong H, et al. A CRISPR screen identifies a pathway required for paraquat-induced cell death. Nat Chem Biol. 2017;13(12):1274-1279. doi:10.1038/nchembio.2499.

Haggarty SJ, Clemons PA, Wong JC, Schreiber SL. Mapping chemical space using molecular descriptors and chemical genetics: deacetylase inhibitors. Comb Chem High Throughput Screen. 2004;7(7):669-76.

Weïwer M, Bittker JA, Lewis TA, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012;22(4):1822-6. doi:10.1016/j.bmcl.2011.09.047.

Weng Z, Rickles RJ, Feng S, et al. Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Mol Cell Biol. 1995;15(10):5627-34.

Wawer M, Peltason L, Bajorath J. Elucidation of structure-activity relationship pathways in biological screening data. J Med Chem. 2009;52(4):1075-80. doi:10.1021/jm8014102.

Shen K, Choe A, Sabatini DM. Intersubunit Crosstalk in the Rag GTPase Heterodimer Enables mTORC1 to Respond Rapidly to Amino Acid Availability. Mol Cell. 2017;68(3):552-565.e8. doi:10.1016/j.molcel.2017.09.026.